The National Academy of Clinical Biochemistry
Laboratory Medicine Practice Guidelines
Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Published Guidelines
Access to Table of Contents
Chinese Translation

We present to clinical chemists, clinicians, and other practitioners of laboratory and clinical medicine the latest update of the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. These guidelines are intended to encourage more appropriate use of tumor marker tests by primary care physicians, hospital physicians and surgeons, specialist oncologists, and other health professionals.

Committee (Author) Disclosures

NACB Committee Members:

Catharine M. Sturgeon
Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK

Michael J. Duffy
Department of Pathology and Laboratory Medicine, St Vincent’s University Hospital and UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

Ulf-Håkan Stenman
Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland

Hans Lilja
Departments of Clinical Laboratories, Urology, and Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

Nils Brünner
Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark

Daniel W. Chan
Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD

Richard Babaian
Department of Urology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Robert C. Bast, Jr
Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX

Barry Dowell
Abbott Laboratories, Abbott Park, IL

Francisco J. Esteva
Departments of Breast Medical Oncology, Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX

Caj Haglund
Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland

Nadia Harbeck
Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Munich, Germany

Daniel F. Hayes
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Mads Holten-Andersen
Section of Biomedicine, Department of Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark

George G. Klee
Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Rolf Lamerz
Department of Medicine, Klinikum of the University Munich, Grosshadern, Germany

Leendert H. Looijenga
Laboratory of Experimental Patho-Oncology, Erasmus MC-University Medical Center Rotterdam, and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Rafael Molina
Laboratory of Biochemistry, Hospital Clinico Provincial, Barcelona, Spain

Hans Jørgen Nielsen
Department of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen, Denmark

Harry Rittenhouse
Gen-Probe Inc, San Diego, CA

Axel Semjonow
Prostate Center, Department of Urology, University Clinic Muenster, Muenster, Germany

Ie-Ming Shih
Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD

Paul Sibley
Siemens Medical Solutions Diagnostics, Glyn Rhonwy, Llanberis, Gwynedd, UK

György Sölétormos
Department of Clinical Biochemistry, Hillerød Hospital, Hillerød, Denmark

Carsten Stephan
Department of Urology, Charité Hospital, Universitätsmedizin Berlin, Berlin, Germany

Lori Sokoll
Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD

Barry R. Hoffman
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

Eleftherios P. Diamandis
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

This LMPG was developed by an independent committee of the NACB. Subsequent publication of these guidelines has been supported by the Academy.